NCT01658605View on ClinicalTrials.gov

A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2013

Study Completion Date

December 31, 2014

Conditions
Colitis, Ulcerative
Interventions
DRUG

GSK1605786

500 mg twice daily administered orally

OTHER

Placebo

500 mg twice daily administered orally

Trial Locations (5)

3000

GSK Investigational Site, Leuven

1105 AZ

GSK Investigational Site, Amsterdam

CB2 0QQ

GSK Investigational Site, Cambridge

SO16 6YD

GSK Investigational Site, Southampton

OX3 9DU

GSK Investigational Site, Oxford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01658605 - A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter